Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 7, 2014, Pages 1254-1262

  Malluche, Hartmut H ^a   Davenport, Daniel L ^a   Canto, Tom ^b   Monier Faugere, Marie Claude ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Scantibodies Laboratory Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR; PARATHYROID HORMONE; PHOSPHORUS; PROCOLLAGEN N PROTEINASE; SCLEROSTIN; UNCLASSIFIED DRUG; ACID PHOSPHATASE; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; ISOENZYME; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; SOST PROTEIN, HUMAN; TARTRATE-RESISTANT ACID PHOSPHATASE;

ADULT; ARTICLE; BONE DENSITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PREDICTION; PROSPECTIVE STUDY; ADVERSE EFFECTS; AGED; BLOOD; COMPARATIVE STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; GENETIC MARKER; HIP; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHOTON ABSORPTIOMETRY; PREDICTIVE VALUE; RADIOGRAPHY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES;

ABSORPTIOMETRY, PHOTON; ACID PHOSPHATASE; ADULT; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; HIP JOINT; HUMANS; ISOENZYMES; KENTUCKY; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84919479006     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09470913     Document Type: Article

References (48)

1. Malluche HH, Monier-Faugere MC: Renal osteodystrophy: What’s in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol 65: 235–242, 2006
2. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945–1953, 2006
3. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1–S201, 2003
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1–S130, 2009
5. Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, Harris TB, Newman AB, Cauley JA, Fried LF; Health, Aging, and Body Composition Study: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7: 1130–1136, 2012
6. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58: 396–399, 2000
7. Erlichman M, Holohan TV: Bone densitometry: Patientswith endstage renal disease. Health Technol Assess (Rockv) 8: 1–27, 1996
8. Malluche HH, Arnala I, Faugere MC: Values of noninvasive techniques in predicting bone histology. Ann Chir Gynaecol 77: 246–250, 1988
9. Cauley JA, Zmuda JM, Wisniewski SR, Krishnaswami S, Palermo L, Stone KL, Black DM, Nevitt MC: Bone mineral density and prevalent vertebral fractures in men and women. Osteoporos Int 15: 32–37, 2004
10. Hui SL, Slemenda CW, Johnston CC Jr.: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809, 1988
11. Leib ES, Lewiecki EM, Binkley N, Hamdy RC; International Society for Clinical Densitometry: Official positions of the International Society for Clinical Densitometry. J Clin Densitom 7:1–6, 2004
12. Malluche HH, Mawad HW, Monier-Faugere MC: Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26: 1368–1376, 2011
13. Fishman WH: Alkaline phosphatase isozymes: Recent progress. Clin Biochem 23: 99–104, 1990
14. Hale LV, Galvin RJ, Risteli J, Ma YL, Harvey AK, Yang X, Cain RL, Zeng Q, Frolik CA, Sato M, Schmidt AL, Geiser AG: PINP: A serum biomarker of bone formation in the rat. Bone 40: 1103–1109, 2007
15. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK: Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res 15: 1337–1345, 2000
16. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett F W, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD: Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284: 10890–10900, 2009
17. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA: Osteocytecontrol of bone formation via sclerostin, a novel BMPantagonist. EMBO J 22: 6267–6276, 2003
18. Padhi D, Jang G, Stouch B, Fang L, Posvar E: Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostinmonoclonal antibody. J Bone Miner Res 26: 19–26, 2011
19. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, ItohN: Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 24113–24117, 2003
20. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr.: The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517–525, 2009
21. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371–379, 2009
22. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G: Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21: 934–945, 2006
23. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE: Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310–1315, 2006
24. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD: Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 192: 261–267, 2007
25. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38–E49, 2006
26. Stĕpan JJ, Silinková -Málková E, Havránek T, Formánková J, Zichová M, Lachmanová J, Straková M, Broulik P, Pacovský V: Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 133: 189–200, 1983
27. Stĕpán JJ, Pospíchal J, Presl J, Pacovský V: Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8: 279–284, 1987
28. de la Piedra C, Torres R, Rapado A, Diaz Curiel M, Castro N: Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 45: 58–60, 1989
29. Cheung MS, Glorieux FH, Rauch F: Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. J Bone Miner Res 24: 669–674, 2009
30. Christiensen C, Hassager C, Riis BJ: Biochemical markers of bone turnover. In: Metabolic Bone Disease and Clinically Related Disorders, edited by Avioli LV, Krane SM, San Diego, CA, Academic Press, 1998
31. Nickolas TL, Cremers S, Zhang A, Thomas V, Stein E, Cohen A, Chauncey R, Nikkel L, Yin MT, Liu XS, Boutroy S, Staron RB, Leonard MB, McMahon DJ, Dworakowski E, Shane E: Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 22: 1560–1572, 2011
32. Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148: 2635–2643, 2007
33. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537–543, 2001
34. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, FoernzlerD, Van HulW: Identification of a 52 kb deletion downstreamof the SOST gene in patients with van Buchem disease. J MedGenet 39: 91–97, 2002
35. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C: Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860–869, 2008
36. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C: Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578–588, 2009
37. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C: Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25: 948–959, 2010
38. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH: Sclerostin andDickkopf-1 in renal osteodystrophy. Clin J AmSoc Nephrol 6: 877–882, 2011
39. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D: The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8: 819–823, 2013
40. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A: Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97: 148–154, 2012
41. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH: Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 26: 2812–2822, 2011
42. Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M: Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 27: 226–230, 2012
43. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R: Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98: 3873–3883, 2013
44. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S: Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26: 373–379, 2011
45. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E: Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. Osteoporos Int 23: 1171–1176, 2012
46. Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, McMahon DJ, Liu XS, Boutroy S, Cremers S, Shane E: Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28: 1811–1820, 2013
47. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA; European Uremic Toxin (EUTox) Work Group: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23: 2017–2025, 2012
48. Ureña P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal M, Cantor T, de Vernejoul MC: Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 18: 2325–2331, 2003